Robbins LLP Reminds Investors it is Investigating Sionna Therapeutics for Potential Securities Violations
Robbins LLP announced it is investigating Sionna Therapeutics officers and directors for potential securities violations and breaches of fiduciary duty. The investigation follows a 92% stock plunge to $4.51 on August 10, 2026, after the company reported disappointing Phase 2a results for SION-719 in cystic fibrosis.
Key figures
- Closing price
- $4.51
- Stock drop percent
- 92%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.